US2012165356A1PendingUtilityA1

Spirocyclic heterocyclic derivatives and methods of their use

Individually held — no corporate assignee on recordPriority: Oct 1, 2003Filed: Oct 17, 2011Published: Jun 28, 2012
Est. expiryOct 1, 2023(expired)· nominal 20-yr term from priority
A61P 37/02A61P 41/00A61P 9/06A61P 9/00A61P 9/10A61P 37/06A61P 43/00A61P 37/08A61P 9/12A61P 25/24A61P 25/08A61P 25/28A61P 25/32A61P 27/06A61P 31/12A61P 25/00A61P 25/14A61P 25/22A61P 25/34A61P 25/16A61P 25/04A61P 25/36A61P 25/30A61P 31/04A61P 29/00A61P 25/18A61P 25/20A61P 11/00C07D 493/10C07D 311/96C07D 491/107A61P 13/02C07D 221/20A61P 1/00A61P 15/00A61P 23/00A61P 11/14C07D 495/10A61P 15/10C07D 401/04A61P 1/04A61P 19/02A61P 13/00A61P 17/06A61P 11/06A61P 15/12A61K 31/438C07D 491/10
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.

Claims

exact text as granted — not AI-modified
1 - 148 . (canceled) 
     
     
         149 . A method for preventing or treating a urogenital tract disorder, comprising the step of:
 administering to a patient in need thereof an effective amount of a compound of the following formula:   
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or N-oxide thereof. 
     
     
         150 . A method according to  claim 149 ,
 wherein said urogenital tract disorder is incontinence or overactive bladder.   
     
     
         151 . A method according to  claim 150 , wherein said incontinence is stress urinary incontinence or urge urinary incontinence. 
     
     
         152 . A method according to  claim 150 , wherein said urogenital tract disorder is overactive bladder. 
     
     
         153 . A method according to  claim 150  further comprising the step of:
 administering to said patient an effective amount of an agent for the treatment of incontinence.

Join the waitlist — get patent alerts

Track US2012165356A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.